Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-1 Adjuvant Chemotherapy in Resected Pancreatic Cancer
NCT04070313Phase 2Terminated
- Sponsor
- TTY Biopharm Company Limited
- Start
- Jul 2019
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tegafur in pancreatic adenocarcinoma (PDAC), sponsored by TTY Biopharm Company Limited. Started Jul 2019; status: terminated.
02
Drugs
tegafur
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04070313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04070313.